癌症单株抗体市场规模、份额及成长分析（按类型、应用、最终用户和地区划分）－2026-2033年产业预测

预计到 2024 年，癌症单株抗体市场规模将达到 1,036 亿美元，到 2025 年将达到 1,226.6 亿美元，到 2033 年将达到 4737.2 亿美元，预测期（2026-2033 年）的复合年增长率为 18.4%。

抗癌单株抗体（mAb）作为癌症治疗的重要组成部分，正日益受到重视，成为化疗、放射线治疗和手术等传统疗法的有力补充。在癌症发病率不断上升、大量新核准获批上市以及前景广阔的新兴治疗方法的推动下，这类治疗方法已展现出对固态肿瘤和骨髓恶性肿瘤的显着疗效。由于单株化疗相比传统化疗副作用较少，其全球市场预计将持续成长。此外，医疗机构越来越多地采用经济高效的生物相似药单株抗体，也将进一步推动市场动态。儘管近年来癌症筛检和治疗可及性方面面临诸多挑战，但对有效癌症治疗方法的强劲需求预示着单株抗体市场前景光明，并有望成为应对这一普遍疾病的关键解决方案。

癌症单株抗体市场驱动因素

癌症单株抗体市场的成长主要受全球癌症发生率上升的推动，这使得人们迫切需要先进且有效的治疗方法。由于单株抗体能够精准靶向癌细胞，与传统治疗方法相比，它们通常能改善患者的治疗效果并最大限度地减少副作用。这种对创新治疗方法日益增长的需求不仅推动了研发投入，也反映了人们对癌症意识的不断提高，从而促进了早期检测。随着人们认识的不断提高，这些治疗方法的市场也将随之扩大，为癌症治疗方法的进一步发展铺路。

癌症单株抗体市场的限制

由于癌症单株抗体治疗方法高成本，该市场面临严峻的挑战。这些成本源自于复杂的生产流程和庞大的研发投入。因此，获得这些重要治疗的机会可能有限，尤其是在低收入者和医疗预算有限的国家。这些治疗方法的不可负担性会给医疗服务提供者带来沉重的负担，并使医疗服务更难以提供。此外，高昂的价格通常意味着患者自付费用增加，进一步限制了他们获得所需治疗的能力，并最终阻碍了市场扩张和可及性。

癌症单株抗体市场趋势

联合治疗的引入是癌症单株抗体市场的一大趋势。这种创新方法将单株抗体与其他治疗方法（例如免疫疗法、标靶治疗和化疗）结合，以增强疗效。透过同时靶向癌症生物学中的多个通路，联合治疗旨在降低抗药性并改善患者预后。特别是，免疫查核点抑制剂与单株抗体的联合应用体现了这项策略，能够促进针对癌细胞的强效免疫反应。随着人们对癌症治疗复杂性的认识不断加深，市场正朝着更个人化、多方面的治疗方案发展，体现了致力于改善患者照护的决心。

目录

介绍

• 调查目标
• 定义
• 市场覆盖范围

调查方法

• 资讯收集
• 二手和一手资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

前景
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 抑制因素
  • 任务
• 波特分析

关键市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

按类型分類的癌症单株抗体市场

• 人性化
• 人类
• 嵌合体体
• 老鼠

按应用分類的癌症单株抗体市场

• 血癌
• 乳癌
• 肺癌
• 黑色素瘤
• 大肠直肠癌
• 肝癌
• 其他的

按最终用户分類的癌症单株抗体市场

• 医院
• 研究所
• 其他的

按地区分類的癌症单株抗体市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲（MEA）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市占率（2025 年）

主要企业简介

• AbbVie Inc.（US）
• Amgen Inc.（US）
• Merck & Co., Inc.（US）
• Bristol-Myers Squibb Company（US）
• Gilead Sciences, Inc.（US）
• Takeda Pharmaceutical Company（Japan）
• AstraZeneca plc（UK）
• Eli Lilly and Company（US）
• Regeneron Pharmaceuticals, Inc.（US）
• BeiGene, Ltd（China）
• Biogen Inc.（US）
• Recordati Industria Chimica e Farmaceutica SpA（Italy）
• Pfizer（US）
• Spectrum Pharmaceuticals, Inc.（US）
• Iovance Biotherapeutics, Inc.（US）
• Exelixis, Inc.（US）
• OncoOne（US）
• CureVac AG（Germany）
• Cellerant Therapeutics, Inc.（US）
• Celltrion, Inc.（South Korea）
• Faron Pharmaceuticals Ltd.（Finland）

Cancer Monoclonal Antibodies Market size was valued at USD 103.6 Billion in 2024 and is poised to grow from USD 122.66 Billion in 2025 to USD 473.72 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

Cancer monoclonal antibodies (mAbs) are increasingly recognized as essential components in cancer treatment, complementing traditional approaches like chemotherapy, radiation, and surgery. This class of therapies has demonstrated significant effectiveness against both solid tumors and hematologic malignancies, propelled by rising cancer incidence, a robust pipeline of new approvals, and promising emerging therapies. The global market is set to expand as mAbs provide treatment options with fewer side effects compared to conventional chemotherapy. Additionally, the growing adoption of cost-effective biosimilar mAbs by healthcare providers will further enhance market dynamics. Despite recent challenges faced in cancer screening and treatment accessibility, the surging demand for effective cancer therapies indicates a favorable outlook for the monoclonal antibodies market as a critical solution against this pervasive disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Monoclonal Antibodies Market Segments Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Cancer Monoclonal Antibodies Market

The growth of the cancer monoclonal antibodies market is significantly driven by the rising incidence of cancer worldwide, leading to a pressing need for advanced and effective treatment options. Monoclonal antibodies offer precise targeting of cancer cells, often resulting in improved patient outcomes and minimized side effects compared to traditional treatments. This growing demand for innovative therapies not only stimulates investment in research and development but also reflects an increasing awareness of cancer that promotes early detection. As awareness continues to expand, so does the market for these therapies, paving the way for further advancements in cancer treatment approaches.

Restraints in the Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies market faces significant challenges due to the elevated costs associated with these therapies. The expenses stem from complex manufacturing techniques and substantial research and development expenditures. As a result, access to these critical treatments may be restricted, particularly for low-income populations and nations with constrained healthcare budgets. The unaffordability of such therapies could place an enormous strain on healthcare providers, making it increasingly burdensome to deliver care. Additionally, the high prices often lead to increased out-of-pocket costs for patients, further limiting their ability to obtain necessary treatments and, ultimately, hindering market expansion and accessibility.

Market Trends of the Cancer Monoclonal Antibodies Market

The cancer monoclonal antibodies market is witnessing a significant trend toward the adoption of combination therapy. This innovative approach integrates monoclonal antibodies with other treatment modalities, including immunotherapies, targeted treatments, and chemotherapy, thereby enhancing therapeutic efficacy. By simultaneously targeting multiple pathways in cancer biology, combination therapies aim to reduce resistance and improve patient outcomes. Notably, the pairing of immune checkpoint inhibitors with monoclonal antibodies exemplifies this strategy, fostering robust immune responses against tumor cells. As the complexities of cancer treatment are increasingly acknowledged, the market is shifting toward more personalized and multifaceted therapeutic options, reflecting a commitment to advancing patient care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cancer Monoclonal Antibodies Market by Type

• Market Overview
• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application

• Market Overview
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End-user

• Market Overview
• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoOne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faron Pharmaceuticals Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments